Table 9 Nominal characteristics for the patients of the survival cohort with normal findings.

From: Prognostic utility and characterization of left ventricular hypertrophy using global thickness

 

All

Normal GT

High GT

p

n

326

300

26

 

Female sex

147

(45%)

140

(47%)

7

(27%)

0.06

Age

47.5

(33–59)

47

(32–59)

56

(40–62)

0.04 *

Death or HHF

29

(9%)

21

(7%)

8

(31%)

 < 0.001 *

Death

21

(6%)

15

(5%)

6

(23%)

0.003 *

LGE by CMR

0

 

0

 

0

 

-

Infarction by CMR

0

 

0

 

0

 

-

Non-ischemic scar by CMR

0

 

0

 

0

 

-

Diabetes mellitus type 2

27

(8%)

22

(7%)

5

(19%)

0.05

Hypertension

106

(33%)

91

(30%)

15

(58%)

0.008 *

CABG prior to CMR

6

(2%)

4

(1%)

2

(1%)

0.08

PCI prior to CMR

16

(5%)

11

(4%)

5

(19%)

0.005 *

  1. Data is shown for the subgroup of the survival cohort with normal findings (no LGE, and findings within the normal range per sex for LVEDVI, LVMI, and LVEF). Age shown as median (interquartile range) and p-value calculated using the Kruskall–Wallis test for difference between the groups, all other data shown as n and percentage and p-value calculated using the Fisher’s exact test for difference between the groups, and * denotes p < 0.05. CABG coronary artery bypass grafting, CMR cardiovascular magnetic resonance, GT global wall thickness, HHF hospitalization for heart failure, LGE late gadolinium enhancement, PCI percutaneous coronary intervention.
Back to article page